It has been reported that BCR/ABL is associated with an increase in proteasome activity42 and that proteasome activity is higher in BMMNCs from patients with CML than in healthy controls43, suggesting that CML cells may be more susceptible to proteasome inhibition. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.